Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Kedi ve Köpeklerin Yangısal Bağırsak Hastalığında Terapötik Helmintler
Therapeutic Helminths in Inflammatory Bowel Disease in Cats and Dogs
Bengü BİLGİÇa, Berna BAYSAL BAKAYb, Sinem ÜLGEN SAKAa, Mehmet Erman ORa
aİstanbul Üniversitesi-Cerrahpaşa Veteriner Fakültesi, İç Hastalıkları ABD, İstanbul, TÜRKİYE
bCumhuriyet Üniversitesi Gürün Meslek Yüksekokulu, Tıbbi Parazitoloji Bölümü, Sivas, TÜRKİYE
Turkiye Klinikleri J Vet Sci. 2020;11(2):92-8
doi: 10.5336/vetsci.2020-75067
Article Language: TR
Full Text
ÖZET
 Yangısal bağırsak hastalığı (IBD) insanlarda olduğu gibi kedi ve köpeklerde de yaygın olarak görülen ishal ve kusma gibi gastrointestinal bulgularla karakterize, yangısal ve otoimmün bir hastalıktır. Günümüzde hijyenik yaşam koşullarının yaygınlaşmasıyla birlikte helmintlerin bağırsağa kolonizasyonunun çeşitli yollarla engellenmesi, hastalığın artışında rol oynayan önemli faktörlerden biri olarak düşünülmektedir. Kedi ve köpeklerde lenfositik-plazmasitik, eozinofilik ve granulomatoz yangı, beşeri hekimlikte ise Krohn hastalığı ve ülseratif kolit şeklinde görülen bu yangısal hastalıkta, Th1 hücreleri tarafından IL-10, IL-12, IL-13, IFNγ gibi sitokinler salınır. Bunun yanı sıra, canlılarda helmint invazyonlarına maruziyet durumunda benzer şekilde bağırsak mukozasında Th2 hücreleri tarafından IL-4, IL-5, IL-9, IL-10, IL-13 gibi sitokinler salınmaktadır. IBD ve helmint invazyonuna maruz kalan canlılarda, bağırsak mukozasından Th1 ve Th2 hücre aracılı salınan bu sitokinlerde kendi aralarında polarizasyonlar şekillenir. Beşeri hekimlikte yapılan pek çok çalışmada, polarizasyonlar sonucu IBD oluşumunda rol oynayan sitokinlerde meydana gelen bu baskılanmaların aşırı yangısal reaksiyonları engellediği ve hastalığın klinik semptomlarında azalmaya neden olduğu gösterilmiştir. veteriner hekimliğinde IBD ile ilgili yapılan bazı çalışmalarda, insanlarda olduğu gibi kedi ve köpeklerde de Th1 aracılı benzer sitokin üretimlerinin olduğu gösterilmiştir. Bu derlemede beşeri hekimlikte bu konu ile ilgili yapılan çalışmalardan yola çıkılarak, helmintlerin terapötik etkinliğinin veteriner hekimliğinde de IBD vakalarında önemli olabileceğine dikkat çekmek amaçlanmıştır.

Anahtar Kelimeler: Yangısal bağırsak hastalıkları; helmintler; köpekler
ABSTRACT
 Inflammatory bowel disease (IBD) is an inflammatory and autoimmune disease characterized by gastrointestinal symptoms such as diarrhea and vomiting which are common in humans, cats and dogs. As hygienic living conditions become widespread today, prevention of helmintic colonizations in the intestine is considered as an important factor that plays a role in increase of the disease. In this inflammatory disease which is seen as Krohn's disease and Ulcerative colitis in human medicine and lymphocytic-plasmacytic, eosinophilic and granulomatous inflammation in veterinary medicine, IL-10, IL12, IL-13 and IFNγ cytokines are released by Th1 cells. On the other hand, in case of helminth infections IL-4, IL-5, IL-9, IL-10, IL-13 released by Th2 cells in the intestinal mucosa. In several studies, some polarizations were shown between these Th1 and Th2 mediated cytokine types. In human medicine, several studies showed that, as a result of polarizations, suppression of cytokines involved in the formation of IBD leads to the prevention of excessive inflammatory reactions and a reduction in the clinical symptoms of the disease. Cats and dogs have similar cytokine production. In this review, based on the studies conducted in human medicine, it is aimed to draw attention to the therapeutic efficacy of helminths may be important in IBD cases in veterinary medicine.

Keywords: Inflammatory bowel diseases; helminths; dogs
REFERENCES:
  1. Chu KM, Watermeyer G, Shelly L, Janssen J, May TD, Brink K, et al. Childhood helminth exposure is protective against inflammatory bowel disease: a case control study in South Africa. Inflamm Bowel Dis. 2013;19(3):614-20.[Crossref] [PubMed] 
  2. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.e42; quiz e30.[Crossref] [PubMed] 
  3. Elliott DE, Urban JF JR, Argo CK, Weinstock JV. Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEB J. 2000;14(12):1848-55.[Crossref] [PubMed] 
  4. Weinstock JV. Helminths and mucosal immune modulation. Ann NY Acad Sci. 2006;1072:356-64.[Crossref] [PubMed] 
  5. Khan WI, Blennerhasset PA, Varghese AK, Chowdhury SK, Omsted P, Deng Y, et al. Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun. 2002;70(11):5931-7.[Crossref] [PubMed] [PMC] 
  6. Weinstock JV, Elliott DE. Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol. 2013;43(3-4):245-51.[Crossref] [PubMed] [PMC] 
  7. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, et al. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013;38(3):255-63.[Crossref] [PubMed] 
  8. Bach JF. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol. 2018;18(2):105-20.[Crossref] [PubMed] 
  9. Elliott DE, Weinstock JV. Where are we on worms? Curr Opin Gastroenterol. 2012;28(6):551-6.[Crossref] [PubMed] [PMC] 
  10. Meloni BP, Thompson RC, Hopkins RM, Reynoldson JA, Gracey M. The prevalence of Giardia and other intestinal parasites in children, dogs and cats from aboriginal communities in the Kimberley. Med J. 1993;158(3):157-9.[Crossref] [PubMed] 
  11. Helmby H. Helminths and our immune system: friend or foe? Parasitol Int. 2009;58(2):121-7.[Crossref] [PubMed] 
  12. Weinstock JV, Elliott DE. Helminth infections decrease host susceptibility to immune-mediated diseases. J Immunol. 2014;193(7):3239-47.[Crossref] [PubMed] [PMC] 
  13. Saidel-Odes L, Odes S. Hygiene hypothesis in inflammatory bowel disease. Ann Gastroenterol. 2014;27(3):189-90.[PubMed] [PMC] 
  14. Waly NE, Stokes CR, Gruffydd-Jones TJ, Day MJ. Immune cell populations in the duodenal mucosa of cats with inflammatory bowel disease. J Vet Intern Med. 2004;18(6):816-25.[Crossref] [PubMed] 
  15. Ohta H, Takada K, Sunden Y, Tamura Y, Osuga T, Lim SY, et al. CD4+ T cell cytokine gene and protein expression in duodenal mucosa of dogs with inflammatory bowel disease. J Vet Med Sci. 2014;76(3):409-14.[Crossref] [PubMed] [PMC] 
  16. Stonehewer J, Simpson JW, Else RW, Macintyre N. Evaluation of B and T lymphocytes and plasma cells in colonic mucosa from healthy dogs and from dogs with inflammatory bowel disease. Res Vet Sci. 1998;65(1):59-63.[Crossref] [PubMed] [PMC] 
  17. Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2003;98(9):2034-41.[Crossref] [PubMed] 
  18. Summers RW, Elliott D.E, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128(4):825-32.[Crossref] [PubMed] 
  19. Croese J, O'neil J, Masson J, Cooke S, Melrose W, Pritchard D, et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut. 2006;55(1):136-7.[Crossref] [PubMed] [PMC] 
  20. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995;101(3):428-35.[Crossref] [PubMed] [PMC] 
  21. Shanahan F. Pathogenesis of ulcerative colitis. Lancet. 1993;342(8868):407-11.[Crossref] [PubMed] 
  22. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today. 1991;12(3):49-53.[Crossref] [PubMed] 
  23. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170(6):2081-95.[Crossref] [PubMed] [PMC] 
  24. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol. 1994;12:227-57.[Crossref] [PubMed] 
  25. Kubin M, Chow JM, Trinchieri G. Differential regulation of interleukin-l2 (IL-l2), tumor necrosis factor alpha and IL-1p production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood journal. 1994;83(7):1847-55.[Crossref] [PubMed] 
  26. Avau A, Matthys P. Therapeutic Potential of Interferon-γ and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Pharmaceuticals (Basel). 2015;8(4):793-815.[Crossref] [PubMed] [PMC] 
  27. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. Clin Invest. 2004;113(10):1490-7.[Crossref] [PubMed] [PMC] 
  28. German AJ, Helps CR, Hall EJ, Day MJ. Cytokine mRNA expression in mucosal biopsies from German shepherd dogs with small intestinal enteropathies. Dig Dis Sci. 2000;45(1):7-17.[Crossref] [PubMed] 
  29. Ridyard AE, Nuttall TJ, Else RW, Simpson JW, Miller HR. Evaluation of Th1, Th2 and immunosuppressive cytokine mRNA expression within the colonic mucosa of dogs with idiopathic lymphocytic-plasmacytic colitis. Vet Immunol Immunopathol. 2002;86(3-4):205-14.[Crossref] [PubMed] 
  30. Jergens AE, Sonea IM, O'Connor AM, Kauffman LK, Grozdanic SD, Ackermann MR, et al. Intestinal cytokine mRNA expression in canine inflammatory bowel disease: a meta-analysis with critical appraisal. Comp Med. 2009;59(2):153-62. Erratum in: Comp Med. 2009 Jun;59(3):220.[PubMed] [PMC] 
  31. Nguyen Van N, Taglinger K, Helps CR, Tasker S, Gruffydd-Jones TJ, Day MJ. Measurement of cytokine mRNA expression in intestinal biopsies of cats with inflammatory enteropathy using quantitative real-time RT-PCR. Vet Immunol Immunopathol. 2006;113(3-4):404-14.[Crossref] [PubMed] 
  32. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific thl-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis. 1996;173(1):269-72.[Crossref] [PubMed] 
  33. Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. Helminth parasites-masters of regulation. Immunol Rev. 2004;201:89-116.[Crossref] [PubMed] 
  34. Maizels R, Yazdanbakhsh M. T-cell regulation in helminth parasite infections: implications for inflammatory diseases. Chem Immunol Allergy. 2008;94:112-23.[Crossref] [PubMed] 
  35. Zhao Y, Liu MY, Wang XL, Liu XL, Yang Y, Zou HB, et al. Modulation of inflammatory bowel disease in a mouse model following infection with Trichinella spiralis. Vet Parasitol. 2013;194(2-4):211-6.[Crossref] [PubMed] 
  36. Adisakwattana P, Nuamtanong S, Kusolsuk T, Chairoj M, Yenchitsomanas PT, Chaisri U. Non-encapsulated Trichinella spp., T. papuae, diminishes severity of DSS induced colitis in mice. Asian Pac J Allergy Immunol. 2013;31:106-14.[Crossref] [PubMed] 
  37. Else KJ, Grencis RK. Cellular immune responses to the murine nematode parasite Trichuris muris. I. Differential cytokine production during acute or chronic infection. Immunology. 1991;72(4):508-13.[PubMed] [PMC] 
  38. Artis D, Potten CS, Else KJ, Finkelman FD, Grencis RK. Trichuris muris: host intestinal epithelial cell hyperproliferation during chronic infection is regulated by interferon-gamma. Exp Parasitol. 1999;92(2):144-53.[Crossref] [PubMed] 
  39. Mendlovic F, Cruz-Rivera M, Diaz-Gandarilla JA, Flores-Torres MA, Avila G, Perfiliev M, et al. Orally administered Taenia solium Calreticulin prevents experimental intestinal inflammation and is associated with a type 2 immune response. PLoS One. 2017;12(10):e0186510.[Crossref] [PubMed] [PMC] 
  40. Heylen M, Ruyssers NE, De Man JG, Timmermans JP, Pelckmans PA, Moreels TG, et al. Worm proteins of Schistosoma mansoni reduce the severity of experimental chronic colitis in mice by suppressing colonic proinflammatory immune responses. PLoS One. 2014;9(10):e110002.[Crossref] [PubMed] [PMC] 
  41. Wang S, Xie Y, Yang X, Wang X, Yan K, Zhong Z, et al. Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice. Parasit Vectors. 2016;9:6.[Crossref] [PubMed] [PMC] 
  42. Schölmerich J, Fellermann K, Seibold FW, Rogler G, Langhorst J, Howaldt S, et al.; International TRUST-2 Study Group. A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease. J Crohns Colitis. 2017;11(4):390-9.[Crossref] [PubMed] [PMC] 
  43. Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn's disease. Gut. 2005;54(1):87-90.[Crossref] [PubMed] [PMC] 
  44. De Majo M, Pugliese M, Galia S, Mazzullo G, La Camera E, Fera MT. Cytokine mRNA quantification in gastro-intestinal biopsies of dogs with idiopathic chronic enteropathies by Real Time RT-PCR: preliminary results. Vet Res Commun. 2008;32 Suppl 1:S275-7.[Crossref] [PubMed] 
  45. Peters IR, Helps CR, Calvert EL, Hall EJ, Day MJ. Cytokine mRNA quantification in duodenal mucosa from dogs with chronic enteropathies by real-time reverse transcriptase polymerase chain reaction. J Vet Intern Med. 2005;19(5):644-53.[Crossref] [PubMed] 
  46. Grzych JM, Pearce E, Cheever A, Caulada ZA, Caspar P, Heiny S, et al. Egg deposition is the major stimulus for the production of Th2 cytokines in murine schistosomiasis mansoni. J Immunol. 1991;146(4):1322-7.[PubMed] 
  47. Sutton TL, Zhao A, Madden KB, Elfrey JE, Tuft BA, Sullivan CA, et al. Anti-Inflammatory mechanisms of enteric Heligmosomoides polygyrus infection against trinitrobenzene sulfonic acid-induced colitis in a murine model. Infect Immun. 2008;76(10):4772-82.[Crossref] [PubMed] [PMC] 
  48. Hunter MM, Wang A, Hirota CL, McKay DM. Neutralizing anti-IL-10 antibody blocks the protective effect of tapeworm infection in a murine model of chemically induced colitis. J Immunol. 2005;174(11):7368-75.[Crossref] [PubMed] 
  49. Elliott DE, Setiawan T, Metwali A, Blum A, Urban JF Jr, Weinstock JV. Heligmosomoides polygyrus inhibits established colitis in IL-10-deficient mice. Eur J Immunol. 2004;34(10):2690-8.[Crossref] [PubMed] 
  50. Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban JF Jr, et al. Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284(3):G385-91.[Crossref] [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com